MedTrace Logo

HDS Plus PBPC Transplant Vs 4 More Courses of FrontLine Therapy in Pts With Aggressive NHL in PR After Induction Therapy

NCT00866203 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 441

Last updated 2009-03-20

No results posted yet for this study

Summary

The study is planned to compare the outcome of aggressive NHL patients in partial remission after four courses of front-line therapy, randomly assigned to receive either additional four courses of the same regimen or a modified HDS program.

Conditions

  • High-Grade Lymphomas

Interventions

DRUG

HDS vs ProMECE/CytaBOM

Sponsors & Collaborators

  • Gruppo Italiano Studio Linfomi

    lead OTHER

Principal Investigators

  • Nicola Di Renzo, MD · GISL

  • Massimo Federico, MD · GISL

  • Maura Brugiatelli, MD · GISL

  • Mario Petrini, MD · GISL

  • Paolo G Gobbi, MD · GISL

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2000-10-31
Completion
2008-04-30

Countries

  • Italy

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00866203 on ClinicalTrials.gov